Abstract: Multi-layered plastic polymeric container useful for the storage and conservation of pharmaceutical compositions, sterile or non sterile, which comprises an inner layer and an outer layer, a gas barrier layer, and adhesive layers.

Abstract: An injector for injecting at least one substance into eggs, comprising an injection body that can be moved between a raised position and an injection position, and equipped with an injection conduit, an injection needle, a guiding and protection tube of the needle subject to elastic stress by elastic means to an idle position and capable of being moved towards a retracted position by pressing its distal end against an egg when the injector is in the injection position. The injector is equipped with control means for controlling the supply of said injection conduit with at least one substance, said tube cooperating with said control means to disable the supply of said injection conduit when said tube is in the idle position and to enable the supply of said conduit when said tube is in the retracted position.

Abstract: The present invention relates to an automatic egg examining device for differentiating between fertilized eggs and unfertilized eggs, comprising emission means (3), which comprise, for each egg to be examined, at least one coherent laser source forming a coherent optical beam (31) directed at an egg (9) to be examined, reception means (4), which receive the light flux passing through the egg, and data processing means (7), which process the light flux received by said reception means in order to determine the state—fertilized or unfertilized—of the egg.

Abstract: The invention relates to new compositions comprising an aldosterone antagonist according to a particular posology for the treatment of heart failure in non-human mammal animals.

Abstract: Method for the qualitative and semi-quantitative detection of a ligand in a sample of a medium to be tested, by (1) diluting at least one lyophilized reaction medium in said sample, (2) incubating the sample in order to carry out an immunoenzymatic method, and (3) observing the resulting colouration.

Abstract: The invention relates to a process for treating lameness with an osseous, articular or osteoarticular component, comprising the administration, to a human or to an animal not suffering from arthritis or from fractures, of an effective amount of a bisphosphonic acid derivative of formula: 1

Abstract: The invention relates to a process for treating lameness with an osseous, articular or osteoarticular component, comprising the administration, to a human or to an animal not suffering from arthritis or from fractures, of an effective amount of a bisphosphonic acid derivative of formula: in which: R1 represents a hydrogen atom, a halogen atom, a hydroxyl, an amino, a mono(C1-C4)alkylamino or a di(C1-C4) alkylamino; R2 represents a halogen atom, a linear alkyl comprising from 1 to 5 carbon atoms which is unsubstituted or substituted with a group chosen from a chlorine atom, a hydroxyl, an amino, a mono (C1-C4) alkylamino or a di(C1-C4) alkylamino; a (C3-C7) cycloalkylamino, or R2 represents a phenoxy, a phenyl, a thiol, a phenylthio, a chlorophenylthio, a pyridyl, a pyridyl-methyl, a 1-pyridyl-1-hydroxymethyl, an imidazolyl-methyl or a 4-thiomorpholinyl, of one of its pharmaceutically acceptable salts or of one of its hydrates.

Abstract: The present invention relates to a process for increasing the egg production and strengthening the eggshells of poultry, which comprises the administration to the animal of at least one bisphosphonic compound chosen from a bisphosphonic acid, a physiologically acceptable salt thereof, hydrates thereof and mixtures thereof.

Abstract: The present invention relates to a stable, nondetergent composition based on fatty acids, in microemulsion form, for administration to humans or animals, comprising: from 5 to 30% by weight of one or more fatty acids with a free carboxylic acid function, as active ingredient; from 5 to 35% by weight of one or more surfactants; from 5 to 30% by weight of one or more C1-C12 alcohols, as cosurfactant; from 5 to 35% by weight of one or more water-soluble compounds with a carbonyl or hydroxyl function; and from 0 to 35% by weight of one or more water-immiscible compounds; the said composition having a pH of less than 6.5.

Abstract: The present invention relates to the use of an active substance selected from the group consisting of tiludronic acid, one of its pharmaceutically acceptable salts, one of its hydrates and mixtures thereof, in the preparation of a medicinal product for preventing and treating osteoporosis in poultry.

Abstract: The invention relates to a process for treating lameness with an osseous, articular or osteoarticular component, comprising the administration, to a human or to an animal not suffering from arthritis or from fractures, of an effective amount of a bisphosphonic acid derivative of formula: in which: R1 represents a hydrogen atom, a halogen atom, a hydroxyl, an amino, a mono(C1-C4)alkylamino or a di(C1-C4)alkylamino; R2 represents a halogen atom, a linear alkyl comprising from 1 to 5 carbon atoms which is unsubstituted or substituted with a group chosen from a chlorine atom, a hydroxyl, an amino, a mono(C1-C4)alkylamino or a di(C1-C4)alkylamino; a (C3-C7) cycloalkylamino, or R2 represents a phenoxy, a phenyl, a thiol, a phenylthio, a chlorophenylthio, a pyridyl, a pyridyl-methyl, a 1-pyridyl-1-hydroxymethyl, an imidazolyl-methyl or a 4-thiomorpholinyl, of one of its pharmaceutically acceptable salts or of one of its hydrates.

Abstract: This invention relates to a method of selecting nonpathogenic bacterial strains capable of binding to the receptor sites for tissue adhesion of pathogenic bacterial strains, comprising the steps consisting in: a) bringing the said receptors into contact in vitro with a bacterial strain to be tested; b) adding an antibody directed against the said receptors, the said antibody being optionally labelled in a detectable manner; c) in the case where the said antibody is itself not labelled in a detectable manner, adding an agent for detecting the antibody; d) detecting the presence of the complex formed between the said antibody and the said receptors.